Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy

American Journal of Kidney Diseases

Volumn 39, Issue 6, 2002, Pages 1143-1152

  Kirpekar, Rashmi ^a,b,c   Yorgin, Peter D ^a,b,c   Tune, Bruce M ^a,b,c   Kim, Mi Kyung ^a,b,c   Sibley, Richard K ^a,b,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Chlorambucil; Cyclophosphamide; Focal segmental glomerulosclerosis (FSGS); Glomerular morphometrics; Minimal change disease (MCD); Outcome; Pathology; Proteinuria

Indexed keywords

CHLORAMBUCIL; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; STEROID;

ARTICLE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG PULSE THERAPY; FEMALE; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX DEPOSITION; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; MESANGIUM; MESANGIUM CELL; MINIMAL CHANGE GLOMERULONEPHRITIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEPHROTIC SYNDROME; OUTCOMES RESEARCH; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; STEROID THERAPY;

EID: 0036272277     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.33382     Document Type: Article

References (41)

1. Intravenous methylprednisolone in minimal change nephrotic syndrome
2. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome
3. Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome
4. The treatment of severe glomerulopathies in children using high dose intravenous methylprednisolone pulses
5. Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents
6. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents
7. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: A long-term follow-up
8. Steroid-resistant nephrotic focal segmental glomerulosclerosis: A treatable disease
9. Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome
10. Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by "pulse" methylprednisolone
11. Damage in systemic lupus erythematosus and its association with corticosteroids
12. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents
13. Glomerular dysfunction in nephrotic humans with minimal change or focal glomerulosclerosis
14. Extent and course of glomerular injury in human membranous glomerulopathy
15. Methylprednisolone pulse therapy for primary glomerulonephritis
16. Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children
17. A clinicopathological study of idiopathic nephrotic syndrome in children
18. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children
19. Pathology of the nephrotic syndrome in children: A report for the International Study of Kidney Disease in Children
20. Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children
21. Quantitative morphometry of renal biopsies prior to cyclosporine in nephrotic syndrome
22. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation
23. Focal-segmental glomerulosclerosis. The relationship between tubular atrophy and segmental sclerosis
24. Focal segmental glomerulosclerosis: Prognostic implications of the cellular lesion
25. Predicting outcome in the idiopathic glomerulopathies
26. Nephrotic syndrome associated with diffuse mesangial hypercellularity: Is it a heterogeneous disease entity?
27. Glomerular basement membrane thickness in minimal change disease. The ultrastructural quantitative study
28. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome
29. Morphological features of primary focal and segmental glomerulosclerosis
30. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy
31. The role of the podocyte in glomerulosclerosis
32. Origin and phenotypic features of hyperplastic epithelial cells in collapsing glomerulopathy
33. Is vacuolization of podocytes and glomerular endothelial cells of prognostic value with respect to FSGS?
34. Podocytes and the development of segmental glomerulosclerosis
35. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy
36. Podocyte detachment and epithelial cell reaction in focal segmental glomerulosclerosis with cellular variants
37. A frequent pathway to glomerulosclerosis: Deterioration of tuft architecture-podocyte damage-segmental sclerosis
38. Progressive renal failure - Inability of podocytes to replicate and the consequences for development of glomerulosclerosis
39. Podocytes lose their adhesive phenotype in focal segmental glomerulosclerosis
40. Crystalline inclusions in the glomerular podocytes in a patient with benign monoclonal gammopathy and focal segmental glomerulosclerosis
41. The role of podocytes in the development of glomerular sclerosis